Skip to Content

Updated data from CheckMate 9LA in advanced NSCLC show continuing benefit

Updated data from the CheckMate 9LA study shows that nivolumab plus ipilimumab with to cycles of chemotherapy gave a significant improvement of overall survival compared to chemotherapy alone in patients with non-small cell lung cancer (NSCLC). Data supports treatment with combinations in first line advanced NSCLC.

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top